Finding Zevalin at a treatment site near you

Although it was approved by the FDA back in 2002, some confusion and uncertainty seems to surround Zevalin, the radioimmunotherapy treatment regimen for relapsed or refractory, low-grade follicular B-cell non-Hodgkin's lymphoma. (It is now also FDA-approved for patients with previously untreated follicular lymphoma who achieve a partial or complete response to first-line chemotherapy).

I see the confusion at SupportGroups.com; it seems that Zevalin is regarded as just exotic enough to stir up that confusion. People do assume—not incorrectly by the way—that you can't simply walk into your local cancer treatment center and expect it to be available.

Part of the nine-day Zevalin therapeutic regimen is administered by health care professionals with specialized training in an area of health care known as nuclear medicine. Why? Because Zevalin works by attaching to the active chemotherapuetic agent a radioactive isotope for delivery to certain cells in the body (you can check out my closer look at Zevalin or read about it at the National Cancer Institute).

Additionally, patients receiving Zevalin enjoy the full attention of an administering staff that often includes a hematology oncologist and a radiation oncologist, and they are closely monitored throughout the entire regimen.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap